Stockscreener 앱 받기
906.86
1.15%
10.33
시장 영업 전:
920.10
13.24
+1.46%
전일 마감가:
$896.53
열려 있는:
$891.41
하루 거래량:
5.91M
Relative Volume:
1.31
시가총액:
$858.30B
수익:
$59.42B
순이익/손실:
$18.41B
주가수익비율:
44.85
EPS:
20.2197
순현금흐름:
$6.44B
1주 성능:
+10.58%
1개월 성능:
+7.98%
6개월 성능:
+10.11%
1년 성능:
+12.49%
1일 변동 폭
$883.64
$915.22
1주일 범위
$809.63
$915.22
52주 변동 폭
$623.78
$935.62
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
906.86 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.86 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
215.89 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
125.01 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.86 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 재확인 | BMO Capital Markets | Outperform |
| 2025-10-14 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development - Yahoo! Finance Singapore
Eli Lilly Invests €2.6 Billion in Netherlands Facility to Produce Oral GLP-1 Treatments for Obesity - geneonline.com
Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs - Stocktwits
Major Stakeholder Sells Massive Eli Lilly & Co Shares! - TipRanks
Eli Lilly plans six additional buildings at Kenosha County campusBizTimes - BizTimes - Milwaukee Business News
Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets. - The Motley Fool
Eli Lilly and Company (NYSE:LLY) Trading Up 1.1%Still a Buy? - MarketBeat
Eli Lilly, Novo Nordisk negotiating deal with Trump administration on obesity drug prices - abcnews.go.com
Eli Lilly, Novo Nordisk negotiating deal with Trump admin on obesity drug prices - Yahoo News UK
Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play - MarketBeat
Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, source says - Reuters
Lilly, Novo Nordisk in pricing, coverage talks with Trump administration on obesity meds: Endpoints - Fierce Pharma
Wall Street gets another reason to like Eli Lilly stock, and DuPont's spin is going to plan - CNBC
Trump administration nears deals for cheaper weight loss drugs with Novo Nordisk, Eli Lilly - statnews.com
Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House - Benzinga
Eli Lilly (LLY) in Talks for Affordable Weight Loss Drug Pricing - GuruFocus
Eli Lilly, Novo reportedly nearing U.S. deals for obesity drug prices (update) - Seeking Alpha
Trump administration is negotiating deals with Eli Lilly and Novo Nordisk to offer weight-loss drugs at reduced prices via TrumprxWSJ - MarketScreener
Eli Lilly (LLY) Nears Agreement on Obesity Drug Pricing with U.S. Government - GuruFocus
Eli Lilly (LLY) and Novo Nordisk (NVO) to Announce Drug Pricing Deals - GuruFocus
Eli Lilly and Novo Nordisk to strike obesity drug pricing deal with White House - Investing.com
Lilly and Novo Nordisk near White House deal on obesity drug prices, Endpoints News reports - Yahoo! Finance Canada
Eli Lilly (LLY) Nears Drug Pricing Agreement with White House - GuruFocus
Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, media reports - TradingView
Lilly and Novo Rise on Report of Deal for Medicare Coverage - Bloomberg.com
Lilly to build a new $3 billion facility in Netherlands - The Pharma Letter
Eli Lilly To Build $3B Netherlands Manufacturing Facility - InkFreeNews.com
Eli Lilly invests $3bn in Dutch manufacturing facility - Global Construction Review
International Markets and Lilly (LLY): A Deep Dive for Investors - Yahoo Finance
Is Eli Lilly a Millionaire Maker? - AOL.com
Lilly announces plan for new $3bn facility to boost manufacturing in Europe - PMLiVE
Lilly boosts oral GLP-1 manufacturing capability with new Netherlands facility - European Pharmaceutical Review
Here’s What Weighed on Eli Lilly and Company’s (LLY) Performance - Insider Monkey
Eli Lilly to build $3B pharmaceutical plant in the Netherlands - MarketScreener
Eli Lilly (LLY) Urges Europe to Eliminate Clawback Taxes - GuruFocus
Fund Update: 18,751 ELI LILLY (LLY) shares added to WELCH & FORBES LLC portfolio - Quiver Quantitative
HSBC Ups Eli Lilly Price Target, EPS Forecasts on 'Solid' Execution, Product Portfolio - 富途牛牛
Analysts recommendations: Apple, Comcast, Crocs, Eli Lilly, Palantir… - MarketScreener
Eli Lilly to invest $3bn in new Dutch manufacturing facility - Pharmaceutical Technology
Eli Lilly to invest $3B in Dutch manufacturing hub - Silicon Canals
US pharma giant Eli Lilly to build factory in the Netherlands - medwatch.com
Are Wall Street Analysts Predicting Eli Lilly Stock Will Climb or Sink? - Barchart.com
Eli Lilly plans to build new USD 3 billion facility in Netherlands - Medical Dialogues
Eli Lilly calls on Europe to ditch clawback taxes on drugmakers - Financial Times
Pharmaceutical Giant Eli Lilly Soars on Blockbuster Drug Performance - AD HOC NEWS
Major Shareholder Cashes Out Big on Eli Lilly Stock! - TipRanks
Eli Lilly and Company (NYSE:LLY) Trading 3.9% Higher on Analyst Upgrade - MarketBeat
Lilly Endowment sells $260m in Eli Lilly shares - Investing.com
Next phase of Eli Lilly's plans in Kenosha County take shape - The Business Journals
Eli Lilly announces Q3 results, $3 billion new site, plans for oral GLP-1 approval - drugdiscoverytrends.com
Eli Lilly (LLY) to Build $3 Billion European Plant to Manufacture Weight-Loss Pill - TipRanks
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.32%
1.75%
자본화:
|
볼륨(24시간):